Inflammatory markers related to microbial translocation among HIV-infected pregnant women: A risk factor of preterm delivery

Journal of Infectious Diseases

Volumn 213, Issue 3, 2016, Pages 343-350

  López, Marta ^a   Figueras, Francesc ^a   Coll, Oriol ^a   Goncé, Anna ^a   Hernández, Sandra ^a   Loncá, Montse ^b   Vila, Jordi ^b   Gratacós, Eduard ^a   Palacio, Montse ^a  

^a CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

HIV; inflammation; lipopolysaccharide; microbial translocation; pregnancy; preterm birth; preterm delivery

Indexed keywords

CD14 ANTIGEN; IMMUNOGLOBULIN M ANTIBODY; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; LIPOPOLYSACCHARIDE BINDING PROTEIN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BIOLOGICAL MARKER; CYTOKINE;

ADULT; ARTICLE; BLACK PERSON; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DELIVERY; DISEASE ASSOCIATION; DISEASE DURATION; EDUCATIONAL STATUS; FEMALE; FETUS; FIRST TRIMESTER PREGNANCY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MATERNAL BLOOD; PREGNANCY OUTCOME; PREGNANT WOMAN; PREMATURE LABOR; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; REPRODUCTIVE HISTORY; RISK FACTOR; SMOKING; SPAIN; SUBSTANCE USE; THIRD TRIMESTER PREGNANCY; UMBILICAL CORD BLOOD; VIRUS TRANSMISSION; CASE CONTROL STUDY; COMPLICATION; GENE EXPRESSION REGULATION; GENETICS; HIV INFECTIONS; INFLAMMATION; MALE; METABOLISM; MULTIVARIATE ANALYSIS; OBSTETRIC LABOR, PREMATURE; PATHOLOGY; PREGNANCY; PREGNANCY COMPLICATION; PROPORTIONAL HAZARDS MODEL;

ADULT; ANTI-HIV AGENTS; BIOMARKERS; CASE-CONTROL STUDIES; COHORT STUDIES; CYTOKINES; FEMALE; GENE EXPRESSION REGULATION; HIV INFECTIONS; HUMANS; INFLAMMATION; MALE; MULTIVARIATE ANALYSIS; OBSTETRIC LABOR, PREMATURE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS;

EID: 84960342927     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv416     Document Type: Article

References (50)

1. Henderson JJ, McWilliam OA, Newnham JP, Pennell CE. Preterm birth aetiology 2004-2008. Maternal factors associated with three phenotypes: spontaneous preterm labour, preterm pre-labour rupture of membranes and medically indicated preterm birth. J Matern Fetal Neonatal Med 2012; 25: 642-7.
2. Petrou S. Economic consequences of preterm birth and low birthweight. BJOG 2003; 110(suppl 20): 17-23.
3. Brocklehurst P, French R. The association between maternal HIV infection and perinatal outcome: a systematic review of the literature and meta-Analysis. Br J Obstet Gynaecol 1998; 105: 836-48.
4. Thorne C, Patel D, Newell ML. Increased risk of adverse pregnancy outcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe. AIDS 2004; 18: 2337-9.
5. Boer K, Nellen JF, Patel D,. et al. The AmRo study: pregnancy outcome in HIV-1-infected women under effective highly active antiretroviral therapy and a policy of vaginal delivery. BJOG 2007; 114: 148-55.
6. Lopez M, Figueras F, Hernandez S,. et al. Association of HIV infection with spontaneous and iatrogenic preterm delivery: effect of HAART. AIDS 2012; 26: 37-43.
7. Haeri S, Shauer M, Dale M,. et al. Obstetric and newborn infant outcomes in human immunodeficiency virus-infected women who receive highly active antiretroviral therapy. Am J Obstet Gynecol 2009; 201: 315.e1-5.
8. Chen JY, Ribaudo HJ, Souda S,. et al. Highly active antiretroviral therapy and adverse birth outcomes among HIV-infected women in Botswana. J Infect Dis 2012; 206: 1695-705.
9. Townsend CL, Cortina-Borja M, Peckham CS, Tookey PA. Antiretroviral therapy and premature delivery in diagnosed HIV-infected women in the United Kingdom and Ireland. AIDS 2007; 21: 1019-26.
10. Rudin C, Spaenhauer A, Keiser O,. et al. Antiretroviral therapy during pregnancy and premature birth: analysis of Swiss data. HIV Med 2011; 12: 228-35.
11. Short CE, Douglas M, Smith JH, Taylor GP. Preterm delivery risk in women initiating antiretroviral therapy to prevent HIV mother-to-child transmission. HIV Med 2014; 15: 233-8.
12. Fiore S, Newell ML, Trabattoni D,. et al. Antiretroviral therapy-Associated modulation of Th1 and Th2 immune responses in HIV-infected pregnant women. J Reprod Immunol 2006; 70: 143-50.
13. Martin F, Taylor GP. Increased rates of preterm delivery are associated with the initiation of highly active antiretrovial therapy during pregnancy: a single-center cohort study. J Infect Dis 2007; 196: 558-61.
14. Sibiude J, Warszawski J, Tubiana R,. et al. Premature delivery in HIV-infected women starting protease inhibitor therapy during pregnancy: role of the ritonavir boost?. Clin Infect Dis 2012; 54: 1348-60.
15. Cotter AM, Garcia AG, Duthely ML, Luke B, O'Sullivan MJ. Is antiretroviral therapy during pregnancy associated with an increased risk of preterm delivery, low birth weight, or stillbirth?. J Infect Dis 2006; 193: 1195-201.
16. Study EC. Exposure to antiretroviral therapy in utero or early life: the health of uninfected children born to HIV-infected women. J Acquir Immune Defic Syndr 2003; 32: 380-7.
17. Ravizza M, Martinelli P, Bucceri A,. et al. Treatment with protease inhibitors and coinfection with hepatitis C virus are independent predictors of preterm delivery in HIV-infected pregnant women. J Infect Dis 2007; 195: 913-4; author reply 916-7.
18. Ezechi OC, David AN, Gab-Okafor CV,. et al. Incidence of and socio-biologic risk factors for spontaneous preterm birth in HIV positive Nigerian women. BMC Pregnancy Childbirth 2012; 12: 93.
19. Watts DH, Williams PL, Kacanek D,. et al. Combination antiretroviral use and preterm birth. J Infect Dis 2013; 207: 612-21.
20. Powis KM, Kitch D, Ogwu A,. et al. Increased risk of preterm delivery among HIVinfected women randomized to protease versus nucleoside reverse transcriptase inhibitor-based HAART during pregnancy. J Infect Dis 2011; 204: 506-14.
21. Tuomala RE, Shapiro DE, Mofenson LM,. et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med 2002; 346: 1863-70.
22. Szyld EG, Warley EM, Freimanis L,. et al. Maternal antiretroviral drugs during pregnancy and infant low birth weight and preterm birth. AIDS 2006; 20: 2345-53.
23. Kourtis AP, Schmid CH, Jamieson DJ, Lau J. Use of antiretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: a meta-Analysis. AIDS 2007; 21: 607-15.
24. Patel K, Shapiro DE, Brogly SB,. et al. Prenatal protease inhibitor use and risk of preterm birth among HIV-infected women initiating antiretroviral drugs during pregnancy. J Infect Dis 2010; 201: 1035-44.
25. Parekh N, Ribaudo H, Souda S,. et al. Risk factors for very preterm delivery and delivery of very-small-for-gestational-Age infants among HIV-exposed and HIVunexposed infants in Botswana. Int J Gynaecol Obstet 2011; 115: 20-5.
26. Romero R, Mazor M. Infection and preterm labor. Clin Obstet Gynecol 1988; 31: 553-84.
27. Romero R, Espinoza J, Kusanovic JP,. et al. The preterm parturition syndrome. BJOG 2006; 113(suppl 3): 17-42.
28. Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm birth. Lancet 2008; 371: 75-84.
29. Brenchley JM, Price DA, Schacker TW,. et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12: 1365-71.
30. Sandler NG, Douek DC. Microbial translocation in HIV infection: causes, consequences and treatment opportunities. Nat Rev Microbiol 2012; 10: 655-66.
31. Brenchley JM, Price DA, Douek DC. HIV disease: fallout from a mucosal catastrophe?. Nat Immunol 2006; 7: 235-9.
32. Kaga N, Katsuki Y, Obata M, Shibutani Y. Repeated administration of low-dose lipopolysaccharide induces preterm delivery in mice: a model for human preterm parturition and for assessment of the therapeutic ability of drugs against preterm delivery. Am J Obstet Gynecol 1996; 174: 754-9.
33. Fidel PL Jr, Romero R, Wolf N,. et al. Systemic and local cytokine profiles in endotoxin-induced preterm parturition in mice. Am J Obstet Gynecol 1994; 170: 1467-75.
34. Cardenas I, Mor G, Aldo P,. et al. Placental viral infection sensitizes to endotoxininduced pre-term labor: a double hit hypothesis. Am J Reprod Immunol 2011; 65: 110-7.
35. Martinez-Lopez DG, Funderburg NT, Cerissi A,. et al. Lipopolysaccharide and soluble CD14 in cord blood plasma are associated with prematurity and chorioamnionitis. Pediatr Res 2014; 75: 67-74.
36. Espinoza J, Chaiworapongsa T, Romero R,. et al. Evidence of participation of soluble CD14 in the host response to microbial invasion of the amniotic cavity and intra-Amniotic inflammation in term and preterm gestations. J Matern Fetal Neonatal Med 2002; 12: 304-12.
37. Gardella C, Hitti J, Martin TR, Ruzinski JT, Eschenbach D. Amniotic fluid lipopolysaccharide-binding protein and soluble CD14 as mediators of the inflammatory response in preterm labor. Am J Obstet Gynecol 2001; 184: 1241-8.
38. Nagao AT, Martinez CC, Vieira VS, Takano OA, Costa-Carvalho BT, Carneiro-Sampaio MM. Placental transfer of IgG and IgG subclass antibodies anti-purified Escherichia coli LPS O16, O6 and O111. Scand J Immunol 1998; 47: 609-14.
39. Gibbs RS, Blanco JD, St Clair PJ, Castaneda YS. Quantitative bacteriology of amniotic fluid from women with clinical intraamniotic infection at term. J Infect Dis 1982; 145: 1-8.
40. Redline RW. Placental pathology: a systematic approach with clinical correlations. Placenta 2008; 29(suppl A): S86-91.
41. Kay R. Goodness of fit methods for the proportional hazards regression model: a review. Rev Epidemiol Sante Publique 1984; 32: 185-98.
42. Taiwo B, Barcena L, Tressler R. Understanding and controlling chronic immune activation in the HIV-infected patients suppressed on combination antiretroviral therapy. Curr HIV/AIDS Rep 2013; 10: 21-32.
43. Jiang W, Lederman MM, Hunt P,. et al. Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis 2009; 199: 1177-85.
44. Merlini E, Bai F, Bellistri GM, Tincati C, d'Arminio Monforte A, Marchetti G. Evidence for polymicrobic flora translocating in peripheral blood of HIV-infected patients with poor immune response to antiretroviral therapy. PLoS One 2011; 6: e18580.
45. Lichtfuss GF, Hoy J, Rajasuriar R, Kramski M, Crowe SM, Lewin SR. Biomarkers of immune dysfunction following combination antiretroviral therapy for HIV infection. Biomark Med 2011; 5: 171-86.
46. Espinoza J, Romero R, Chaiworapongsa T,. et al. Lipopolysaccharide-binding protein in microbial invasion of the amniotic cavity and human parturition. J Matern Fetal Neonatal Med 2002; 12: 313-21.
47. Aagaard K, Ma J, Antony KM, Ganu R, Petrosino J, Versalovic J. The placenta harbors a unique microbiome. Sci Transl Med 2014; 6: 237ra65.
48. Prince AL, Antony KM, Chu DM, Aagaard KM. The microbiome, parturition, and timing of birth: more questions than answers. J Reprod Immunol 2014; 104-105: 12-9.
49. Townsend CL, Tookey PA, Newell ML, Cortina-Borja M. Antiretroviral therapy in pregnancy: balancing the risk of preterm delivery with prevention of mother-tochild HIV transmission. Antivir Ther 2010; 15: 775-83.
50. Awad N, Khatib N, Ginsberg Y,. et al. N-Acetyl-cysteine (NAC) attenuates LPSinduced maternal and amniotic fluid oxidative stress and inflammatory responses in the preterm gestation. Am J Obstet Gynecol 2011; 204: 450.e15-20.